My blood has been to CDC-Atlanta twice now. Facilitated by the United Nations, I have been out of the USA twice now to meet with Nobel-awarded scientist(s). My blood has been to Path labs in Washington, DC and a 100 other scientific places. In a conversation I had, with the Head of CDC's Retroviral Division, he mentioned Tulane's work to me. I do not have any retroviral activity in my body, so I know that this does not pertain tome. But, perhaps it might explain other CFS cases. Be well.
New retrovirus, HIAP-II (Source: http://www.autoimmune.com/Non-HIVAIDSTest.html)
Idiopathic CD4+ T-lymphocytopenia, or Non-HIV AIDS, is associated with a patented retroviral particle called Human Intracisternal A-Type Particle-Type II, or HIAP-II.
Autoimmune Technologies is developing viral protein antibody tests based on HIAP-II that the Company believes will be useful in diagnosing Non-HIV AIDS. These tests may have other important uses as well, including use in the screening of blood products.
These tests are still in the laboratory stage and are not yet generally available for investigational, clinical, or other use.
...
Non-HIV AIDS patients may comprise perhaps one percent of all AIDS patients. While the majority of Non-HIV AIDS patients do not belong to any of the risk groups such as blood transfusion recipients, male homosexuals, and intravenous drug abusers in which AIDS was first identified, some Non-HIV AIDS patients do belong to these groups. This suggests that Non-HIV AIDS may also be transmissible.
Research conducted at Tulane University Medical Center suggests that Non-HIV AIDS is associated with a retroviral particle called Human Intracisternal A-Type Particle-Type II, or HIAP-II. Antibodies to this particle have been found in a high percentage of patients with Non-HIV AIDS. Tulane has patented HIAP-II, and Autoimmune Technologies is licensing HIAP-II technology in order to develop screening and diagnostic tests and therapies for Non-HIV AIDS and to study the possibility of generating vaccines against Non-HIV AIDS, autoimmune disease, and AIDS.
http://www.autoimmune.com/Non-HIVAIDSGen.html
www.cfsstraighttalk.blogspot.com
New retrovirus, HIAP-II (Source: http://www.autoimmune.com/Non-HIVAIDSTest.html)
Idiopathic CD4+ T-lymphocytopenia, or Non-HIV AIDS, is associated with a patented retroviral particle called Human Intracisternal A-Type Particle-Type II, or HIAP-II.
Autoimmune Technologies is developing viral protein antibody tests based on HIAP-II that the Company believes will be useful in diagnosing Non-HIV AIDS. These tests may have other important uses as well, including use in the screening of blood products.
These tests are still in the laboratory stage and are not yet generally available for investigational, clinical, or other use.
...
Non-HIV AIDS patients may comprise perhaps one percent of all AIDS patients. While the majority of Non-HIV AIDS patients do not belong to any of the risk groups such as blood transfusion recipients, male homosexuals, and intravenous drug abusers in which AIDS was first identified, some Non-HIV AIDS patients do belong to these groups. This suggests that Non-HIV AIDS may also be transmissible.
Research conducted at Tulane University Medical Center suggests that Non-HIV AIDS is associated with a retroviral particle called Human Intracisternal A-Type Particle-Type II, or HIAP-II. Antibodies to this particle have been found in a high percentage of patients with Non-HIV AIDS. Tulane has patented HIAP-II, and Autoimmune Technologies is licensing HIAP-II technology in order to develop screening and diagnostic tests and therapies for Non-HIV AIDS and to study the possibility of generating vaccines against Non-HIV AIDS, autoimmune disease, and AIDS.
http://www.autoimmune.com/Non-HIVAIDSGen.html
www.cfsstraighttalk.blogspot.com